Imagine your doctor recommends a cancer treatment. You trust them completely — and you should be able to. But what if the system they work within quietly rewards them for choosing one drug over another, not because it works better, but because it costs more?

That's the reality of how most chemotherapy is paid for in the United States. It's called buy-and-bill, and it's a payment model that ties a cancer center's financial survival to the price of the drugs it administers. Understanding this system doesn't mean distrusting your oncologist. It means seeing the invisible currents that shape the care you receive.

Here's how it works. When your oncologist gives you chemotherapy, the cancer center doesn't just charge for the infusion service. It first buys the drug at one price, then bills your insurance at a higher price. The difference — the markup — is how many cancer centers keep their lights on. Under Medicare, this reimbursement is typically set at the drug's average sales price plus six percent.

That six percent sounds small until you do the math. Six percent of a $100 drug is $6. Six percent of a $10,000 drug is $600. The more expensive the drug, the more the center earns. This means a cancer center that consistently uses cheaper but equally effective treatments actually loses money compared to one that defaults to expensive options.

This isn't a quirky accounting detail. It's the financial foundation of oncology practice in America. Many cancer centers — especially independent community practices — depend on drug margins for 50 to 70 percent of their total revenue. The drug isn't just the treatment. It's the business model.

Takeaway

When a healthcare provider's revenue is directly proportional to the price of the drug they prescribe, the system has embedded a financial conflict into the heart of clinical decision-making — even when no one intends it.

Let's be clear: most oncologists are deeply committed to their patients. They didn't go through years of training to chase drug markups. But systems shape behavior in ways individuals don't always recognize. When two drugs treat the same cancer with similar outcomes, but one generates ten times more revenue for the practice, the expensive option doesn't need a villain to become the default. It just needs a system that rewards it.

Research backs this up. Studies have shown that when reimbursement formulas change — reducing the profit margin on expensive drugs — prescribing patterns shift toward less costly alternatives. The patients don't get worse. The outcomes hold. What changes is the financial incentive. This tells us something uncomfortable: at least some portion of expensive drug use is driven not by clinical superiority, but by economic gravity.

This bias extends beyond individual drugs. It can influence whether a patient is recommended chemotherapy at all versus surgery, radiation, or watchful waiting. When the business model depends on infusions, the entire treatment conversation tilts — subtly, systemically — toward the chair and the IV drip.

Takeaway

You don't need bad actors to get bad outcomes. When a system rewards a particular choice financially, that choice becomes the path of least resistance — even among well-meaning professionals.

The good news is that people who study this problem have proposed solutions. The most promising fall under the umbrella of alternative payment models. Instead of paying doctors more when they use expensive drugs, these models pay a flat fee for managing an episode of cancer care — regardless of which drugs are chosen. The incentive flips: now the center benefits from choosing the most effective treatment at the best value.

Medicare's Oncology Care Model and its successor, the Enhancing Oncology Model, have tested this approach. Early results are mixed but encouraging. Costs came down modestly. Quality didn't suffer. And importantly, oncologists reported feeling freed to make decisions based purely on clinical evidence rather than revenue pressure.

But reform faces real resistance. Cancer centers that have built their entire financial structure around drug margins can't pivot overnight. Rural and community practices worry that flat payments won't cover their costs. And pharmaceutical companies have little reason to support a system that reduces demand for their most expensive products. Change is possible — but it requires acknowledging that the current system was designed for a different era.

Takeaway

The best way to remove financial bias from treatment decisions isn't to ask doctors to ignore money — it's to design payment systems where doing the right thing and staying financially viable are the same thing.

None of this means your oncologist is trying to profit off your illness. What it means is that the system surrounding your care has financial incentives baked into its structure — incentives that don't always align with your best interests.

Understanding buy-and-bill doesn't make you a cynic. It makes you an informed participant. Ask about treatment alternatives. Ask why one drug was chosen over another. The more patients understand the economics of their care, the more pressure the system faces to finally put outcomes ahead of margins.